This research project will work with stroke survivors and their families. In year one, we will design a healthy living programme for stroke survivors and their families. The programme will provide information, education and support. It will help people to learn how to manage their own lifestyle risk factors.
People who have survived a previous stroke or transient ischaemic attack (TIA) are at particularly high risk of subsequent, ‘recurrent’ stroke with 30% having another stroke in the following five years. High blood pressure is the most important reversible risk factor for having a recurrent stroke.
A system of supported decision making and self-management for the prevention of secondary stroke
This study will investigate whether early initiation of direct anticoagulant drugs will be as safe as later initiation in stroke patients with an abnormal heart rhythm (atrial fibrillation). It will also investigate whether early initation could lead to fewer recurrent strokes.
The importance of variability in blood pressure after acute stroke
This research is focused on assessing the relationship between the variability of the blood flow through the blood vessels supplying the brain, and the risk of stroke in patients who have already had a stroke or “mini-stroke” (TIA) in the past.
Understanding the difficulty in controlling emotions after stroke
No two strokes are alike - the damage from each stroke leaves its own unique signature on a person's brain and behaviour. The current project will investigate how different types of stroke affect a person's long term recovery or deterioration
Cerebral venous thrombosis (CVT) is an unusual form of stroke. It is little researched largely because it accounts for less than 1% of all strokes. The study will provide a much better understanding for the reasons underlying CVT, which is an unusual but very important cause of stroke in young (mainly female) adults.
The overall purpose of this research is to make laboratory stroke experiments more reliable and useful for informing how to design human clinical trials with a higher chance of success.